CD274 Antibodies

CD274 antibodies, also known as PD-L1 (Programmed Death-Ligand 1) antibodies, are specialized antibodies designed to target and detect the CD274/PD-L1 protein, which is a critical immune checkpoint molecule. PD-L1 is expressed on the surface of various cell types, including cancer cells and immune cells, and it interacts with its receptor, PD-1 (Programmed Death-1), on T cells. 

Content: CD274/PD-L1 antibodies can be used to detect and study PD-L1 expression in various contexts:

• Cancer Cells: PD-L1 is frequently overexpressed in many types of cancers, including lung cancer, melanoma, renal cell carcinoma, and breast cancer, where it helps tumor cells evade immune detection by suppressing T-cell function. Anti-PD-L1 antibodies are widely used to assess PD-L1 levels in tumors and their microenvironment, helping to evaluate the likelihood of response to immunotherapy.
• Immune Cells: PD-L1 is also expressed on activated immune cells such as macrophages, dendritic cells, and T cells. Studying PD-L1 expression on immune cells helps understand how the immune system regulates itself and how immune checkpoint pathways contribute to immune tolerance and chronic inflammation.

Applications: CD274/PD-L1 antibodies are widely used in various research and clinical applications, including:

• Western Blotting (WB): To detect and quantify PD-L1 protein levels in cell lysates or tissue extracts. Western blotting with PD-L1 antibodies is essential for studying the regulation of PD-L1 at the protein level, examining how factors like inflammation, hypoxia, or drug treatment influence its expression.
• ELISA (Enzyme-Linked Immunosorbent Assay): PD-L1 antibodies are used in ELISA to measure soluble PD-L1 levels in blood or other biological fluids. Soluble PD-L1 is a form of PD-L1 that circulates in the blood and can serve as a biomarker for certain cancers and immune disorders. ELISA assays help quantify soluble PD-L1 for research on its role in disease progression and therapeutic response.
• Immunoprecipitation (IP): To study protein-protein interactions involving PD-L1. Using PD-L1 antibodies in IP experiments allows researchers to investigate how PD-L1 interacts with other proteins, such as PD-1, or how it may be regulated by signaling pathways in the cell.

CD274/PD-L1 antibodies are indispensable tools in cancer immunotherapy research and clinical diagnostics. They help assess PD-L1 expression, identify patients who may benefit from immune checkpoint inhibitors, and provide insights into the mechanisms of immune escape in cancer.